Actively Recruiting
FOSTER Platform Evaluating Cabozantinib Maintenance Therapy Versus Supportive Care in Osteosarcoma Patients
Led by Gustave Roussy, Cancer Campus, Grand Paris · Updated on 2026-10-26
530
Participants Needed
77
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating osteosarcoma, a type of bone cancer affecting children and adults, through the FOSTER evolving study platform. This European Phase III trial, sponsored by Gustave Roussy, focuses on improving survival by studying tumor biology deeply and evaluating multiple treatments over time. The FOSTER-CabOS trial, part of this platform, specifically tests cabozantinib as a maintenance therapy after standard treatment to prevent relapse in patients with high-grade osteosarcoma. Participants in the study are randomized to receive either cabozantinib, a tyrosine kinase inhibitor taken orally daily for up to 12 cycles of 28 days each, or best supportive care based on country standards. The platform allows ongoing evaluation of different therapeutic strategies from diagnosis through relapse with adaptable treatment arms. The maintenance phase targets patients who have completed first-line systemic and local treatment and are in remission or have stable disease. During the trial, participants undergo various assessments including blood and tumor sample collection, imaging, clinical evaluations, and laboratory tests to monitor treatment effects, compliance, quality of life, and adverse events. Researchers will track event-free survival, overall survival, quality of life measures, and biological markers for up to eight years. Safety and treatment adherence are closely followed during and after the cabozantinib treatment period, with long-term follow-up planned to evaluate lasting outcomes.
CONDITIONS
Brief Title
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Research Team
N
Nathalie GASPAR, Docteur
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here